Botanix Pharmaceuticals Valuation Multiples

Botanix Pharmaceuticals Overview

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.

Founded

1984

HQ

Employees

10

Website

botanixpharma.com

Sectors

BiopharmaceuticalsBioTechCannaTechViceTech

Financials (LTM)

Revenue: $21M

EBITDA: ($42M)

EV

$64M

Valuation Multiples

Multiples.vc

Start free trial

Botanix Pharmaceuticals Financials

Botanix Pharmaceuticals reported last 12-month revenue of $21M and negative EBITDA of ($42M).

In the same LTM period, Botanix Pharmaceuticals generated $15M in gross profit, ($42M) in EBITDA losses, and had net loss of ($49M).

Botanix Pharmaceuticals P&L

In the most recent fiscal year, Botanix Pharmaceuticals reported revenue of $4M and EBITDA of ($47M).

Botanix Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Botanix Pharmaceuticals Stock Performance

Botanix Pharmaceuticals has current market cap of $88M, and enterprise value of $64M.

Botanix Pharmaceuticals' stock price is $0.04.

Botanix Pharmaceuticals Valuation Multiples

Botanix Pharmaceuticals trades at 3.1x EV/Revenue multiple, and (1.5x) EV/EBITDA.

Botanix Pharmaceuticals Financial Valuation Multiples

As of March 23, 2026, Botanix Pharmaceuticals has market cap of $88M and EV of $64M.

Equity research analysts estimate Botanix Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Botanix Pharmaceuticals has a P/E ratio of (1.8x).

Botanix Pharmaceuticals Margins & Growth Rates

Botanix Pharmaceuticals' revenue in the last 12 month grew by 148%.

Botanix Pharmaceuticals' revenue per employee in the last FY averaged $2.1M.

Botanix Pharmaceuticals' rule of 40 is (51%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Botanix Pharmaceuticals' rule of X is 170% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Botanix Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Botanix Pharmaceuticals M&A Activity

Botanix Pharmaceuticals acquired XXX companies to date.

Last acquisition by Botanix Pharmaceuticals was on XXXXXXXX, XXXXX. Botanix Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Botanix Pharmaceuticals Investment Activity

Botanix Pharmaceuticals invested in XXX companies to date.

Botanix Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Botanix Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).